Acadia expects Federal Circuit decision in Nuplazid patent appeal in first half of 2027
ACAD•Acadia expects a Federal Circuit decision in its Nuplazid patent appeal in the first half of 2027; the 34 mg capsule patent is expected to remain protected until February 2038 if the judgment is upheld.
1. Appeal timeline
Acadia Pharmaceuticals expects a Federal Circuit decision in its Nuplazid patent appeal in the first half of 2027. Nuplazid 34 mg capsule patent protection is expected to last until February 2038 if the judgment is upheld.
